Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Short-term Activity Ratios (Summary)

Bristol-Myers Squibb Co., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Less: Average payables payment period

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


An analysis of short-term activity ratios reveals a distinct shift in operational efficiency starting in the fourth quarter of 2024, particularly regarding inventory management. While working capital utilization has exhibited significant volatility, a consistent pattern of extending payment terms to suppliers is observed throughout the period.

Inventory Management and Processing
Inventory turnover ratios remained relatively stable, fluctuating between 3.70 and 4.77 from March 2022 through September 2024. A marked improvement occurred on December 31, 2024, when the turnover ratio rose to 5.46 and remained elevated, averaging approximately 5.20 through March 2026. This trend is inversely reflected in the average inventory processing period, which peaked at 102 days in September 2024 before dropping sharply to a stabilized range of 67 to 70 days. This transition indicates a significant optimization in inventory throughput and a reduction in the time capital is tied up in stock.
Accounts Payable Cycle
The payables turnover ratio demonstrates consistent fluctuation, generally ranging between 3.05 and 3.88. The average payables payment period indicates a strategic reliance on supplier credit, with payment cycles typically spanning 94 to 120 days. A notable outlier occurred in June 2025, where the payment period extended to 140 days, coinciding with the lowest observed turnover ratio of 2.61, suggesting a temporary deceleration in cash outflows to vendors.
Working Capital Utilization
Working capital turnover exhibits the highest degree of volatility among the analyzed metrics. A significant surge was observed in the first half of 2024, peaking at 15.56 in March 2024, which suggests a period of highly efficient use of net current assets to generate revenue. Following this peak, the ratio moderated and fluctuated between 5.84 and 8.09 throughout 2025 and early 2026, indicating a return to more stabilized, though variable, operational levels.

Turnover Ratios


Average No. Days


Inventory Turnover

Bristol-Myers Squibb Co., inventory turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of products sold, excludes amortization of acquired intangible assets
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Inventory turnover = (Cost of products sold, excludes amortization of acquired intangible assetsQ1 2026 + Cost of products sold, excludes amortization of acquired intangible assetsQ4 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ3 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ2 2025) ÷ Inventories
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The inventory turnover ratio demonstrates a cyclical pattern characterized by an initial period of stability, a subsequent decline in efficiency, and a final phase of significant improvement and stabilization.

Stability and Initial Performance (2022)
During the 2022 fiscal year, inventory turnover remained relatively consistent, fluctuating within a narrow range between 4.33 and 4.77. This stability was supported by cost of products sold maintaining a baseline between 2,353 million and 2,720 million US dollars, while inventories were held steady between 2,074 million and 2,339 million US dollars.
Efficiency Decline (2023 – September 2024)
A downward trend in turnover efficiency is observed starting in early 2023, reaching a low of 3.57 by September 30, 2024. This decline corresponds with a period where inventory levels grew more rapidly than the cost of products sold. Specifically, inventories increased from 2,605 million US dollars in March 2023 to a peak of 3,332 million US dollars in September 2024, suggesting an accumulation of stock that outpaced sales activity.
Recovery and Optimization (December 2024 – March 2026)
A sharp reversal in the trend occurred in December 2024, where the turnover ratio jumped to 5.46. This improvement was driven by a simultaneous spike in the cost of products sold to 4,812 million US dollars and a reduction in inventory levels to 2,557 million US dollars. This elevated level of efficiency persisted through March 31, 2026, with the ratio stabilizing between 5.18 and 5.46, indicating a more optimized balance between inventory holdings and product throughput.

Payables Turnover

Bristol-Myers Squibb Co., payables turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of products sold, excludes amortization of acquired intangible assets
Accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Payables turnover = (Cost of products sold, excludes amortization of acquired intangible assetsQ1 2026 + Cost of products sold, excludes amortization of acquired intangible assetsQ4 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ3 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ2 2025) ÷ Accounts payable
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a cyclical pattern in the management of accounts payable relative to the cost of products sold over the observed period from March 2022 to March 2026. While both costs and liabilities have generally trended upward, the efficiency of payables turnover exhibits recurring seasonal fluctuations.

Cost of Products Sold Trends
Expenditures for products sold demonstrate a general upward trajectory, rising from 2,471 million US$ in March 2022 to 3,421 million US$ by March 2026. A distinct pattern of year-end volatility is evident, with significant spikes occurring in December 2024 (4,812 million US$) and December 2025 (4,096 million US$), indicating period-end surges in production costs or inventory procurement.
Accounts Payable Dynamics
Accounts payable balances have increased over the analyzed timeframe, growing from 2,944 million US$ in March 2022 to 4,234 million US$ in March 2026. A notable peak occurred in June 2025, where obligations reached 5,427 million US$, the highest level in the dataset. This expansion in payables suggests an increase in the utilization of supplier credit to fund operations.
Payables Turnover Ratio Interpretation
The payables turnover ratio fluctuates between a high of 3.88 in December 2024 and a low of 2.61 in June 2025. A recurring quarterly trend is observable, where the ratio typically peaks in the September quarters (e.g., 3.82 in 2022, 3.75 in 2023, and 3.42 in 2025), signaling faster settlement of obligations. Conversely, the sharp decline to 2.61 in June 2025 indicates a period of slower payment velocity, coinciding with the peak in total accounts payable. The overall stability of the ratio, generally remaining between 3.0 and 3.9, suggests a consistent long-term strategy for managing supplier credit, despite short-term operational variances.

Working Capital Turnover

Bristol-Myers Squibb Co., working capital turnover calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Net product sales
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Working capital turnover = (Net product salesQ1 2026 + Net product salesQ4 2025 + Net product salesQ3 2025 + Net product salesQ2 2025) ÷ Working capital
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a period of significant volatility in working capital management against a backdrop of relatively stable net product sales. While revenue streams remained consistent, the efficiency with which working capital was utilized to generate these sales fluctuated considerably between March 2022 and March 2026.

Net Product Sales Stability
Net product sales exhibited a steady profile throughout the analyzed period, generally fluctuating between 10.6 billion and 12.1 billion US dollars. The absence of dramatic swings in revenue indicates that the variance in the working capital turnover ratio is driven by changes in the balance sheet components rather than operational revenue growth or decline.
Working Capital Volatility
Working capital demonstrated substantial instability, ranging from a low of 2.85 billion US dollars in March 2024 to a peak of 9.51 billion US dollars in December 2023. This volatility suggests periodic shifts in the company's current asset and liability structure, which directly impacted the efficiency ratios.
Working Capital Turnover Trends
The working capital turnover ratio showed erratic movement, characterized by several distinct phases. From March 2022 to December 2023, the ratio fluctuated between 4.60 and 10.47. A significant spike occurred in the first half of 2024, reaching a peak of 15.56 in March 2024. This peak was the result of a sharp contraction in working capital coinciding with stable sales, representing a period of maximum efficiency in capital utilization. Following this peak, the ratio gradually normalized throughout 2025, returning to a range between 6.20 and 8.09, before declining to 5.84 by March 2026.
Correlation and Operational Insight
An inverse correlation is evident between the absolute value of working capital and the turnover ratio. The most efficient operational phases, such as Q1 2024, were not the result of increased sales, but rather a reduction in the working capital base. Conversely, periods of lower turnover, such as December 2023 and March 2026, coincide with increases in working capital, suggesting a less lean approach to short-term asset and liability management during those intervals.

Average Inventory Processing Period

Bristol-Myers Squibb Co., average inventory processing period calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of inventory management efficiency from March 31, 2022, to March 31, 2026, reveals three distinct phases: a period of relative stability, a phase of declining efficiency, and a subsequent period of rapid optimization and stabilization.

Inventory Processing Period Trends
From March 2022 through December 2022, the average inventory processing period remained relatively stable, fluctuating between 76 and 84 days. However, a gradual upward trend emerged throughout 2023 and the first three quarters of 2024, with the processing period peaking at 102 days in September 2024. This increase indicates a slowing of inventory movement and a longer duration of capital tied up in stock.
A significant shift occurred in December 2024, where the processing period dropped sharply to 67 days. Following this correction, the metric stabilized, maintaining a consistent range between 69 and 70 days through March 31, 2026.
Inventory Turnover Correlation
The inventory turnover ratio demonstrates a strong inverse correlation with the processing period. During the period of efficiency decline (March 2023 to September 2024), turnover ratios trended downward, reaching a minimum of 3.57. This suggests a reduction in the frequency with which the total inventory was replaced during the period.
Parallel to the reduction in processing days starting in December 2024, the turnover ratio increased substantially, rising to a peak of 5.46 and maintaining a baseline above 5.18 through the end of the observed period. This transition indicates a marked improvement in operational efficiency and a more aggressive inventory liquidation cycle.
Operational Insights
The volatility observed between 2023 and September 2024 suggests potential headwinds in supply chain management or an intentional buildup of safety stock. The subsequent abrupt transition to a lower processing period (approximately 30 days shorter than the peak) indicates the implementation of more effective inventory control measures or a significant increase in sales volume relative to stock levels.

Average Payables Payment Period

Bristol-Myers Squibb Co., average payables payment period calculation (quarterly data)

Microsoft Excel
Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q1 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An analysis of the operating activity indicates a recurring cyclical pattern in the management of accounts payable. The company demonstrates a consistent trend of fluctuating payment velocities, with systematic accelerations and decelerations occurring across the fiscal quarters.

Payables Turnover
The turnover ratio exhibits a seasonal oscillation, generally peaking in the third or fourth quarters of the year. Highs reaching between 3.75 and 3.90 are frequently observed in September and December, suggesting a more rapid settlement of obligations during these periods. Conversely, the ratio typically declines during the first half of the year, with a notable trough occurring in June 2025, where the ratio dropped to its lowest point of 2.61.
Average Payables Payment Period
The payment period moves inversely to the turnover ratio, fluctuating between a minimum of 94 days and a maximum of 140 days. A distinct seasonal pattern is evident every September, where the payment period consistently contracts to its lowest quarterly levels, ranging from 94 to 106 days. This indicates a periodic acceleration of cash outflows to suppliers. For most of the observed period, the payment cycle remains stable between 94 and 120 days, maintaining a relatively consistent credit utilization strategy.

A significant deviation from the established trend occurred on June 30, 2025, when the average payables payment period spiked to 140 days. This anomaly represents the longest duration of credit utilization in the analyzed period and corresponds directly with the lowest recorded turnover ratio. However, this extension was temporary, as the payment period reverted to 107 days by September 30, 2025, returning to the historical quarterly norm.